Quoin Pharmaceuticals Ltd (DE:2EB0)

NASDAQ:2EB0

2EB0

Quoin Pharmaceuticals

RESEARCH TOOLSreports

Quoin Pharmaceuticals (2EB0) Price & Analysis

0 Followers

2EB0 Stock Chart & Stats

€12.60

Market closed

€12.60

Day’s Range― - ―

52-Week Range€3.36 - €25.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)0.00

Market Cap

€7.64M

Enterprise Value-€148.40K

Total Cash (Recent Filing)€3.12M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta-0.48

Next Earnings

Aug 06, 2026

EPS Estimate

-1.4

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-18.45

Shares Outstanding2,008,418

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)1.65

Price to Sales (P/S)0.00

P/FCF Ratio-1.60

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€30.14

Price Target Upside139.20% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-5.26

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial DesignOpenness to alternative designs such as randomized withdrawal or randomized delayed start could enable faster enrollment and produce more meaningful treatment comparisons for a visible skin disease.

Commercial Potential And FinancingEncouraging clinical data for QRX003 lowers development risk and supports the potential to be the first approved therapy for Netherton syndrome, while existing cash and potential financing could fund the planned pivotal program.

Regulatory PathwayFDA indicated that a single Phase 3 study may be sufficient, which could reduce trial costs and shorten the approval pathway for QRX003.

Bears Say

Potential For Additional TrialsThe statement that a single study 'may be sufficient' leaves ambiguity and raises the possibility that regulators could request additional studies or clarifying data, risking longer development timelines and higher costs.

Regulatory Data ExpectationsFDA's cautious phrasing implies that data will need to be exceptionally robust for regulatory acceptance, increasing the approval risk for QRX003.

Quoin Pharmaceuticals News

Quoin Pharmaceuticals granted Orphan Drug Designation for QRX003 in Japan

Quoin Pharmaceuticals (QNRX) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted Orphan Drug...

5d ago

QNRX

Quoin Pharmaceuticals submits QRX003 IND application to FDA

Quoin Pharmaceuticals (QNRX) announced the submission of an investigational new drug, or IND, application to the FDA for...

6d ago

QNRX

Quoin Wins Japan Orphan Drug Status for QRX003

Quoin Pharmaceuticals ( ($QNRX) ) has shared an announcement. On March 11, 2026, Quoin Pharmaceuticals announced that Japan’s...

4d ago

QNRX

Quoin Pharmaceuticals initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Quoin Pharmaceuticals (QNRX) with a Buy rating and $30 price target Quoin is...

1M ago

QNRX

Quoin Pharmaceuticals provides regulatory update on QRX009 topical rapamycin

Quoin Pharmaceuticals (QNRX) provided a clinical and regulatory update for its QRX009 topical rapamycin development programs. The company...

1M ago

QNRX

Quoin’s QRX003 Trial Moves Forward In Rare Skin Disease, Keeping QNRX On Investor Watch

Quoin Pharmaceuticals Ltd ($QNRX) announced an update on their ongoing clinical study. The multicenter study “A Multicenter, Open-label...

2M ago

QNRX

Financing Covenants Put Quoin Pharmaceuticals at Heightened Risk of Funding Shortfall and Program Delays

Quoin Pharmaceuticals Ltd (QNRX) has disclosed a new risk, in the Debt & Financing category. Quoin Pharmaceuticals Ltd....

2M ago

QNRX

Quoin Pharmaceuticals price target raised to $35 from $25 at Alliance Global

Alliance Global raised the firm’s price target on Quoin Pharmaceuticals (QNRX) to $35 from $25 and keeps a...

2M ago

QNRX

Quoin Pharmaceuticals Ltd – ADR trading resumes

09:38 EDT Quoin Pharmaceuticals (QNRX) Ltd – ADR trading resumes Published first on TheFly – the ultimate source...

3M ago

QNRX

Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause

09:33 EDT Quoin Pharmaceuticals (QNRX) Ltd – ADR trading halted, volatility trading pause Published first on TheFly –...

3M ago

QNRX

Quoin Pharmaceuticals provides update following QRX003 Type C meeting with FDA

Quoin Pharmaceuticals (QNRX) provided a clinical and regulatory update from its recent constructive Type C meeting with the...

3M ago

QNRX

Quoin Wins FDA Fast Track for QRX003 in Netherton

Quoin Pharmaceuticals ( ($QNRX) ) has provided an announcement. On March 11, 2026, Quoin Pharmaceuticals announced that the...

3M ago

QNRX

Quoin Pharmaceuticals receives U.S. Fast Track Designation to QRX003

Quoin Pharmaceuticals (QNRX) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to QRX003...

3M ago

QNRX

QNRX Earnings this Week: How Will it Perform?

Quoin Pharmaceuticals Ltd (QNRX) is scheduled to report 4th quarter earnings on 03/12/2026. Regarding Q4 estimates, Wall Street...

3M ago

QNRX

2EB0 FAQ

What was Quoin Pharmaceuticals Ltd’s price range in the past 12 months?

Quoin Pharmaceuticals Ltd lowest stock price was €3.36 and its highest was €25.00 in the past 12 months.

What is Quoin Pharmaceuticals Ltd’s market cap?

Quoin Pharmaceuticals Ltd’s market cap is €7.64M.

When is Quoin Pharmaceuticals Ltd’s upcoming earnings report date?

Quoin Pharmaceuticals Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 58 days.

How were Quoin Pharmaceuticals Ltd’s earnings last quarter?

Quoin Pharmaceuticals Ltd released its earnings results on May 07, 2026. The company reported -€1.536 earnings per share for the quarter, beating the consensus estimate of -€1.883 by €0.347.

Is Quoin Pharmaceuticals Ltd overvalued?

According to Wall Street analysts Quoin Pharmaceuticals Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Quoin Pharmaceuticals Ltd pay dividends?

Quoin Pharmaceuticals Ltd does not currently pay dividends.

What is Quoin Pharmaceuticals Ltd’s EPS estimate?

Quoin Pharmaceuticals Ltd’s EPS estimate is -1.4.

How many shares outstanding does Quoin Pharmaceuticals Ltd have?

Quoin Pharmaceuticals Ltd has 2,008,418 shares outstanding.

What happened to Quoin Pharmaceuticals Ltd’s price movement after its last earnings report?

Quoin Pharmaceuticals Ltd reported an EPS of -€1.536 in its last earnings report, beating expectations of -€1.883. Following the earnings report the stock price went up 2%.

Which hedge fund is a major shareholder of Quoin Pharmaceuticals Ltd?

Currently, no hedge funds are holding shares in DE:2EB0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Quoin Pharmaceuticals Ltd

Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.

Quoin Pharmaceuticals (2EB0) Earnings & Revenues

Historic Earnings Reports

2EB0 Stock 12 Month Forecast

Average Price Target

€30.14

▲(139.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","35":"€35","10.25":"€10.25","18.5":"€18.5","26.75":"€26.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34.4443948,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€34.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.13884545,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€30.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.8332961,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€25.83</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,10.25,18.5,26.75,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.96,6.304953446153846,8.64990689230769,10.994860338461537,13.339813784615384,15.684767230769229,18.029720676923073,20.37467412307692,22.719627569230767,25.06458101538461,27.409534461538456,29.754487907692305,32.099441353846146,{"y":34.4443948,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.96,5.973757342307692,7.987514684615385,10.001272026923077,12.01502936923077,14.028786711538462,16.042544053846154,18.05630139615385,20.07005873846154,22.083816080769232,24.097573423076923,26.11133076538462,28.12508810769231,{"y":30.13884545,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.96,5.642561238461538,7.3251224769230765,9.007683715384616,10.690244953846154,12.372806192307692,14.05536743076923,15.737928669230769,17.420489907692307,19.103051146153845,20.785612384615384,22.468173623076922,24.15073486153846,{"y":25.8332961,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.5,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.92,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.75,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.08,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.88,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >